Next Article in Journal
Self-Injuries and Their Functions with Respect to Suicide Risk in Adolescents with Conduct Disorder: Findings from a Path Analysis
Next Article in Special Issue
Impact of Post-Procedural Change in Left Ventricle Systolic Function on Survival after Percutaneous Edge-to-Edge Mitral Valve Repair
Previous Article in Journal
Acute Kidney Disease and Mortality in Acute Kidney Injury Patients with COVID-19
Previous Article in Special Issue
Initial Results after the Implementation of an Edge-To-Edge Transcatheter Tricuspid Valve Repair Program
Review

Caval Valve Implantation (CAVI): An Emerging Therapy for Treating Severe Tricuspid Regurgitation

1
Department of Cardiology, Germans Trias University Hospital, 08916 Badalona, Spain
2
Department of Cardiothoracic and Vascular Surgery, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania
3
Department of Cardiology, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania
4
Department of Cardiology, Cleveland Clinic, Cleveland, OH 44195, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Leor Perl, Rodrigo Estévez-Loureiro, Xavier Freixa, Dabit Arzamendi and Dan Haberman
J. Clin. Med. 2021, 10(19), 4601; https://doi.org/10.3390/jcm10194601
Received: 8 September 2021 / Revised: 27 September 2021 / Accepted: 28 September 2021 / Published: 7 October 2021
Severe tricuspid regurgitation remains a challenging heart-valve disease to effectively treat with high morbidity and mortality at mid-term. Currently guideline-directed medical treatment is limited to escalating dose of diuretics, and the rationale and timing of open-heart surgery remains controversial. Emerging percutaneous therapies for severe tricuspid regurgitation continue to show promising results in early feasibility studies. However, randomized trial data is lacking. Additionally, many patients are deemed unsuitable for these emerging therapies due to anatomical or imaging constraints. Given the technical simplicity of the bicaval valve implantation (CAVI) technique compared to other transcatheter devices, CAVI is postulated as a suitable alternative for a wide variety of patients affected with severe+ tricuspid regurgitation. In this review we illustrate the current evidence and ongoing uncertainties of CAVI, focusing on the novel CAVI-specific devices. View Full-Text
Keywords: tricuspid regurgitation; Transcatheter Valves Therapies; bicaval valve implantation; review tricuspid regurgitation; Transcatheter Valves Therapies; bicaval valve implantation; review
Show Figures

Figure 1

MDPI and ACS Style

Abdul-Jawad Altisent, O.; Benetis, R.; Rumbinaite, E.; Mizarien, V.; Codina, P.; Gual-Capllonch, F.; Spitaleri, G.; Fernandez-Nofrerias, E.; Bayes-Genis, A.; Puri, R. Caval Valve Implantation (CAVI): An Emerging Therapy for Treating Severe Tricuspid Regurgitation. J. Clin. Med. 2021, 10, 4601. https://doi.org/10.3390/jcm10194601

AMA Style

Abdul-Jawad Altisent O, Benetis R, Rumbinaite E, Mizarien V, Codina P, Gual-Capllonch F, Spitaleri G, Fernandez-Nofrerias E, Bayes-Genis A, Puri R. Caval Valve Implantation (CAVI): An Emerging Therapy for Treating Severe Tricuspid Regurgitation. Journal of Clinical Medicine. 2021; 10(19):4601. https://doi.org/10.3390/jcm10194601

Chicago/Turabian Style

Abdul-Jawad Altisent, Omar, Rimantas Benetis, Egle Rumbinaite, Vaida Mizarien, Pau Codina, Francisco Gual-Capllonch, Giosafat Spitaleri, Eduard Fernandez-Nofrerias, Antoni Bayes-Genis, and Rishi Puri. 2021. "Caval Valve Implantation (CAVI): An Emerging Therapy for Treating Severe Tricuspid Regurgitation" Journal of Clinical Medicine 10, no. 19: 4601. https://doi.org/10.3390/jcm10194601

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop